Aptevo Therapeutics reports third-quarter net loss of $7.5 million

Reuters11-06

Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third-quarter net loss of $7.5 million

Aptevo Therapeutics Inc. reported a net loss of $7.5 million, or $2.23 per share, for the three months ended September 30, 2025, compared to a net loss of $5.1 million, or $357.86 per share, for the same period in 2024. Research and development expenses increased to $4.0 million from $3.1 million, primarily due to higher mipletamig and employee costs, offset by lower costs on ALG.APV-527. General and administrative expenses rose to $3.6 million from $2.1 million, mainly due to higher employee costs. A non-cash dividend of $1.5 million was recorded related to the down round feature of warrants, increasing net loss attributable to common shareholders to $9.0 million for EPS purposes. As of September 30, 2025, cash and cash equivalents totaled $21.1 million, with an additional $4.1 million raised in October, resulting in a proforma cash position of $25.2 million. The company states it has sufficient cash resources to meet projected operating requirements for at least twelve months from the date of issuance of the financial statements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097578) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581493093?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581493093","market":"fut","top_or_hot":-1,"title":"Aptevo Therapeutics reports third-quarter net loss of $7.5 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third-quarter net loss of $7.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> reported a net loss of $7.5 million, or $2.23 per share, for the three months ended September 30, 2025, compared to a net loss of $5.1 million, or $357.86 per share, for the same period in 2024. Research and development expenses increased to $4.0 million from $3.1 million, primarily due to higher mipletamig and employee costs, offset by lower costs on ALG.APV-527. General and administrative expenses rose to $3.6 million from $2.1 million, mainly due to higher employee costs. A non-cash dividend of $1.5 million was recorded related to the down round feature of warrants, increasing net loss attributable to common shareholders to $9.0 million for EPS purposes. As of September 30, 2025, cash and cash equivalents totaled $21.1 million, with an additional $4.1 million raised in October, resulting in a proforma cash position of $25.2 million. The company states it has sufficient cash resources to meet projected operating requirements for at least twelve months from the date of issuance of the financial statements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097578) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Therapeutics reports third-quarter net loss of $7.5 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Therapeutics reports third-quarter net loss of $7.5 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third-quarter net loss of $7.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> reported a net loss of $7.5 million, or $2.23 per share, for the three months ended September 30, 2025, compared to a net loss of $5.1 million, or $357.86 per share, for the same period in 2024. Research and development expenses increased to $4.0 million from $3.1 million, primarily due to higher mipletamig and employee costs, offset by lower costs on ALG.APV-527. General and administrative expenses rose to $3.6 million from $2.1 million, mainly due to higher employee costs. A non-cash dividend of $1.5 million was recorded related to the down round feature of warrants, increasing net loss attributable to common shareholders to $9.0 million for EPS purposes. As of September 30, 2025, cash and cash equivalents totaled $21.1 million, with an additional $4.1 million raised in October, resulting in a proforma cash position of $25.2 million. The company states it has sufficient cash resources to meet projected operating requirements for at least twelve months from the date of issuance of the financial statements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097578) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APVO","symbol_name":"Aptevo Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6DpyM5:1","article_id":"2581493093","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581493093","pubTimestamp":1762434369,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptevo Therapeutics Inc. reported a net loss of $7.5 million, or $2.23 per share, for the three months ended September 30, 2025, compared to a net loss of $5.1 million, or $357.86 per share, for the same period in 2024. Research and development expenses increased to $4.0 million from $3.1 million, primarily due to higher mipletamig and employee costs, offset by lower costs on ALG.APV-527. General and administrative expenses rose to $3.6 million from $2.1 million, mainly due to higher employee costs. A non-cash dividend of $1.5 million was recorded related to the down round feature of warrants, increasing net loss attributable to common shareholders to $9.0 million for EPS purposes. As of September 30, 2025, cash and cash equivalents totaled $21.1 million, with an additional $4.1 million raised in October, resulting in a proforma cash position of $25.2 million. The company states it has sufficient cash resources to meet projected operating requirements for at least twelve months from th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APVO":"Aptevo Therapeutics Inc.","EBS":"Emergent Biosolutions","BK4139":"生物科技","BK4583":"猴痘概念"},"translate_title":"Aptevo Therapeutics报告第三季度净亏损750万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APVO":0.9,"EBS":0.9},"content_text":"Aptevo Therapeutics reports third-quarter net loss of $7.5 million\n    \n\nAptevo Therapeutics Inc. reported a net loss of $7.5 million, or $2.23 per share, for the three months ended September 30, 2025, compared to a net loss of $5.1 million, or $357.86 per share, for the same period in 2024. Research and development expenses increased to $4.0 million from $3.1 million, primarily due to higher mipletamig and employee costs, offset by lower costs on ALG.APV-527. General and administrative expenses rose to $3.6 million from $2.1 million, mainly due to higher employee costs. A non-cash dividend of $1.5 million was recorded related to the down round feature of warrants, increasing net loss attributable to common shareholders to $9.0 million for EPS purposes. As of September 30, 2025, cash and cash equivalents totaled $21.1 million, with an additional $4.1 million raised in October, resulting in a proforma cash position of $25.2 million. The company states it has sufficient cash resources to meet projected operating requirements for at least twelve months from the date of issuance of the financial statements.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097578) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581493093","isCrawlerRequest":true}